Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	663.56M +34.7%
Revenue (ttm)	236.21M +58.5%
Net Income	72.66M
EPS	5.47
Shares Out	12.29M
PE Ratio	9.87
Forward PE	14.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,978
Average Volume	42,045
Open	55.20
Previous Close	54.90
Day's Range	54.00 - 55.20
52-Week Range	37.50 - 59.70
Beta	0.46
RSI	49.63
Earnings Date	Feb 17, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infectiv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 180
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.